Drs. Friedlander, Koshkin on Long-Term Follow-Up of EV-103

By Terence Friedlander, MD, Vadim Koshkin, MD - June 15, 2023

Terence Friedlander, MD, and Vadim Koshkin, MD, both of the University of California, San Francisco, highlight the 18-month outcomes data from the EV-103 study on enfortumab vedotin plus pembrolizumab as first-line treatment for metastatic urothelial carcinoma.

View more ASCO 2023 videos.

Advertisement
Advertisement